Pharmazz
Pharmazz, Inc. is a biopharmaceutical company based in Willowbrook, Illinois, focused on critical care therapeutics, with a strong product pipeline and extensive clinical development activities.
Company Overview
Pharmazz, Inc. is a biopharmaceutical company headquartered in Willowbrook, Illinois, USA. The company is focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. It has a robust pipeline in various stages of clinical development, aimed at addressing major health conditions such as hypovolemic shock, COVID-19 with ARDS, septic shock, and more.
Subsidiaries
Pharmazz India Private Limited is a key subsidiary of Pharmazz, Inc. This majority-owned entity extends the company's reach in India, employing over 80 personnel. Pharmazz, Inc. has entered into strategic licensing agreements with Dr. Reddy's Laboratories and Sun Pharma to market its products Centhaquine (Lyfaquin®) and Tyvalzi (Sovateltide) in India, respectively.
Product Pipeline and Development
Pharmazz, Inc. boasts a promising drug pipeline with leading programs targeting diverse medical conditions. The company is actively enrolled in various clinical trials, including a Phase 3 study for Sovateltide, which has received a Special Protocol Assessment Agreement from the U.S. FDA. Pharmazz, Inc. is also conducting a multi-centric, open-labeled study of Centhaquine (Lyfaquin®) as a resuscitative agent, with the 214th patient already enrolled.
Key Partnerships and Licensing Agreements
Pharmazz, Inc. has forged significant licensing agreements to bolster its product reach. The company has licensed exclusive worldwide rights to several molecules from Midwestern University, USA, which are aimed at treating critically ill patients. Additionally, Pharmazz has partnered with Dr. Reddy's Laboratories and Sun Pharma for marketing its key products in India.
Clinical Trials and FDA Approvals
Pharmazz, Inc. is actively involved in several critical clinical trials. The U.S. FDA has approved its Investigational New Drug (IND) application for a Phase 3 study in cerebral ischemic stroke. Additionally, the company has enrolled the ninth patient in a Phase II clinical trial of Sovateltide targeted at hypoxic-ischemic encephalopathy in neonates. Pharmazz continues to advance its clinical assets with a strong focus on regulatory compliance and efficacy.